376 related articles for article (PubMed ID: 37429366)
1. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.
Reddy KR; McLerran D; Marsh T; Parikh N; Roberts LR; Schwartz M; Nguyen MH; Befeler A; Page-Lester S; Tang R; Srivastava S; Rinaudo JA; Feng Z; Marrero JA
Gastroenterology; 2023 Oct; 165(4):1053-1063.e6. PubMed ID: 37429366
[TBL] [Abstract][Full Text] [Related]
2. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
Ganne-Carrié N; Chaffaut C; Bourcier V; Archambeaud I; Perarnau JM; Oberti F; Roulot D; Moreno C; Louvet A; Dao T; Moirand R; Goria O; Nguyen-Khac E; Carbonell N; Antonini T; Pol S; de Ledinghen V; Ozenne V; Henrion J; Péron JM; Tran A; Perlemuter G; Amiot X; Zarski JP; Beaugrand M; Chevret S;
J Hepatol; 2018 Dec; 69(6):1274-1283. PubMed ID: 30092234
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis.
Kim MN; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim DY
Scand J Gastroenterol; 2019 Oct; 54(10):1283-1290. PubMed ID: 31593481
[No Abstract] [Full Text] [Related]
4. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort.
Paranaguá-Vezozzo DC; Ono SK; Alvarado-Mora MV; Farias AQ; Cunha-Silva M; França JI; Alves VA; Sherman M; Carrilho FJ
Ann Hepatol; 2014; 13(4):386-93. PubMed ID: 24927609
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network.
Borges KA; Dai J; Parikh ND; Schwartz M; Nguyen MH; Roberts LR; Befeler AS; Srivastava S; Rinaudo JA; Feng Z; Marrero JA; Reddy KR
Contemp Clin Trials; 2019 Jan; 76():49-54. PubMed ID: 30439517
[TBL] [Abstract][Full Text] [Related]
6. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
[TBL] [Abstract][Full Text] [Related]
7. Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India.
Paul SB; Sreenivas V; Gulati MS; Madan K; Gupta AK; Mukhopadhyay S; Panda SK; Acharya SK
Indian J Gastroenterol; 2007; 26(6):274-8. PubMed ID: 18431010
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
[TBL] [Abstract][Full Text] [Related]
9. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H
J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614
[TBL] [Abstract][Full Text] [Related]
10. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
Colapietro F; Maisonneuve P; Lytvyak E; Beuers U; Verdonk RC; van der Meer AJ; van Hoek B; Kuiken SD; Brouwer JT; Muratori P; Aghemo A; Carella F; van den Berg AP; Zachou K; Dalekos GN; Di Zeo-Sánchez DE; Robles M; Andrade RJ; Montano-Loza AJ; van den Brand FF; Slooter CD; Macedo G; Liberal R; de Boer YS; Lleo A; ;
J Hepatol; 2024 Jan; 80(1):53-61. PubMed ID: 37802188
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies.
Tayob N; Corley DA; Christie I; Almers L; Rahal AK; Richardson P; White DL; Davila J; Kanwal F; El-Serag HB
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1443-1450.e6. PubMed ID: 32768590
[TBL] [Abstract][Full Text] [Related]
13. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ
World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for hepatocellular carcinoma in patients with liver cirrhosis.
Macías Rodríguez MA; Rendón Unceta P; Tejada Cabrera M; Infante Hernández JM; Correro Aguilar F; Díaz García F; Benítez Rodríguez E; Mangas Rojas A; Martín Herrera L
Rev Esp Enferm Dig; 2000 Jul; 92(7):458-69. PubMed ID: 11026763
[TBL] [Abstract][Full Text] [Related]
16. Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index.
Nartey YA; Awuku YA; Agyei-Nkansah A; Duah A; Bampoh SA; Ayawin J; Asibey SO; Björkström NK; Ye W; Afihene MY; Roberts LR; Plymoth A
BMC Gastroenterol; 2020 Dec; 20(1):428. PubMed ID: 33357229
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis.
Tayob N; Christie I; Richardson P; Feng Z; White DL; Davila J; Corley DA; Kanwal F; El-Serag HB
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1886-1893.e5. PubMed ID: 30557738
[TBL] [Abstract][Full Text] [Related]
18. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
19. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study.
Hallager S; Ladelund S; Kjaer M; Madsen LG; Belard E; Laursen AL; Gerstoft J; Røge BT; Grønbaek KE; Krarup HB; Christensen PB; Weis N
J Viral Hepat; 2018 Jan; 25(1):47-55. PubMed ID: 28750141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
